NCT04039230 2026-03-16
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
Massachusetts General Hospital
Phase 1/2 Active not recruiting
Clinical Trials
9 trialsNCT03974217 2026-02-25
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT02286687 2026-01-02
Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03672773 2025-11-10
TRIO-US L-07
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT02912572 2025-07-10
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03964532 2025-05-21
TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer
Georgetown University
Phase 1/2 Active not recruiting
NCT04846478 2025-04-17
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT03911973 2024-06-07
Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers
Big Ten Cancer Research Consortium
Phase 1/2 Active not recruiting